World's Best Scientists 2026 revealed!
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 111 5257 4932 288 275 785 58347

Martin Reck publications per year

The chart shows the history of publications by Martin Reck between 1990 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Martin Reck published across 37 years, from 1990 to 2026, averaging 26.7 papers a year. Output peaked at 102 publications in 2023. 37 of the 987 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1990 to 2026. Vertical axis: number of publications, 0 to 102. Peak 102 publications in 2023. 1990: 1 publication 1991: 0 publications 1992: 3 publications 1993: 0 publications 1994: 0 publications 1995: 0 publications 1996: 0 publications 1997: 1 publication 1998: 1 publication 1999: 1 publication 2000: 1 publication 2001: 1 publication 2002: 0 publications 2003: 6 publications 2004: 7 publications 2005: 19 publications 2006: 14 publications 2007: 26 publications 2008: 22 publications 2009: 28 publications 2010: 30 publications 2011: 32 publications 2012: 39 publications 2013: 27 publications 2014: 47 publications 2015: 50 publications 2016: 64 publications 2017: 71 publications 2018: 60 publications 2019: 82 publications 2020: 67 publications 2021: 95 publications 2022: 25 publications 2023: 102 publications 2024: 28 publications 2025: 36 publications 2026: 1 publication
1990 2026

987 publications in total across all disciplines

View publications per year as a table
Martin Reck: publications per year, 1990 to 2026
Year Publications
1990 1
1991 0
1992 3
1993 0
1994 0
1995 0
1996 0
1997 1
1998 1
1999 1
2000 1
2001 1
2002 0
2003 6
2004 7
2005 19
2006 14
2007 26
2008 22
2009 28
2010 30
2011 32
2012 39
2013 27
2014 47
2015 50
2016 64
2017 71
2018 60
2019 82
2020 67
2021 95
2022 25
2023 102
2024 28
2025 36
2026 1
Total 987
Download as CSV

Martin Reck publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Martin Reck sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 781–800 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 785 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217 785
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Martin Reck D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Martin Reck sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 110–111 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429 111
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Martin Reck is affiliated with the LungenClinic Grosshansdorf in Germany and has contributed extensively to the fields of pulmonary and respiratory medicine as well as oncology. Their research output covers a wide range of topics related to lung cancer treatments, cancer immunotherapy, and cancer genomics.

The primary fields of study for Martin Reck include Medicine, with significant work in the subfields of Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Surgery.

Main research topics covered by Martin Reck encompass:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research

Martin Reck has frequently published in the following venues:

  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • Lung Cancer

Recent notable publications include:

  • "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer," 2023, New England Journal of Medicine
  • "IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC," 2021, Journal of Thoracic Oncology
  • "Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC," 2020, Journal of Thoracic Oncology
  • "First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial," 2021, Journal of Thoracic Oncology

Frequent co-authors collaborating with Martin Reck include:

  • Enriqueta Felip
  • Edward B. Garon
  • Luis Paz-Ares
  • Solange Peters
  • Makoto Nishio

Best Publications

  • Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †

    S Novello;F Barlesi;R Califano;R Califano;T Cufer

  • Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

    Martin Reck;Joachim von Pawel;Petr Zatloukal;Rodryg Ramlau

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

    Thomas J. Lynch;Igor Bondarenko;Alexander Luft;Piotr Serwatowski

  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

    Martin Reck;Rolf Kaiser;Anders Mellemgaard;Jean-Yves Douillard

  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    M Reck;S Popat;N Reinmuth;Dirk De Ruysscher

  • Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

    M. Reck;J Von Pawel;P. Zatloukal;R. Ramlau

  • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

    M. Reck;I. Bondarenko;A. Luft;P. Serwatowski

  • Management of non-small-cell lung cancer: recent developments.

    Martin Reck;David F. Heigener;Tony Mok;Jean Charles Soria

  • Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

    Luis Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  • PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

    Luis G. Paz-Ares;Filippo de Marinis;Mircea Dediu;Michael Thomas

  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

    Jean Yves Douillard;Frances A. Shepherd;Vera Hirsh;Tony Mok

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

Frequent Co-Authors

Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Silvia Novello
Silvia Novello University of Turin
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Joachim von Pawel
Joachim von Pawel The University of Texas MD Anderson Cancer Center
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
Edward B. Garon
Edward B. Garon University of California, Los Angeles
Tony Mok
Tony Mok Chinese University of Hong Kong
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring a career in medicine but are interested in flexible or alternative pathways, various online health degrees can open new doors. Nurse practitioners seeking to advance their education remotely may consider the most affordable online dnp programs, which offer an accessible route to a Doctor of Nursing Practice degree.

For those passionate about pharmacy but concerned about tuition costs, options exist for the cheapest online pharmacy school. These accredited programs allow students to earn advanced pharmacy degrees while managing expenses.

The healthcare industry also needs skilled informatics professionals. An online bachelor's in health information management is ideal for those interested in the intersection of healthcare, data, and technology.

Additionally, if you’re looking for entry-level positions, pursuing a career in medical billing and coding is an option. While costs can vary, the average cost of medical billing and coding program might surprise you with its affordability and potential for future growth.

Best Scientists Citing Martin Reck

Trending Scientists

Recently Published Articles